| Literature DB >> 17987038 |
S Staibano1, F Merolla, D Testa, R Iovine, M Mascolo, V Guarino, M D Castellone, M Di Benedetto, V Galli, S Motta, R M Melillo, G De Rosa, M Santoro, A Celetti.
Abstract
Laryngeal dysplasia is a common clinical concern. Despite major advancements, a significant number of patients with this condition progress to invasive squamous cell carcinoma. Osteopontin (OPN) is a secreted glycoprotein, whose expression is markedly elevated in several types of cancers. We explored OPN as a candidate biomarker for laryngeal dysplasia. To this aim, we examined OPN expression in 82 cases of dysplasia and in hyperplastic and normal tissue samples. OPN expression was elevated in all severe dysplasia samples, but not hyperplastic samples, with respect to matched normal mucosa. OPN expression levels correlated positively with degree of dysplasia (P=0.0094) and negatively with disease-free survival (P<0.0001). OPN expression was paralleled by cell surface reactivity for CD44v6, an OPN functional receptor. CD44v6 expression correlated negatively with disease-free survival, as well (P=0.0007). Taken as a whole, our finding identify OPN and CD44v6 as predictive markers of recurrence or aggressiveness in laryngeal intraepithelial neoplasia, and overall, point out an important signalling complex in the evolution of laryngeal dysplasia.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17987038 PMCID: PMC2360266 DOI: 10.1038/sj.bjc.6604070
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Clinicopathological features of studied laryngeal intraepithelial neoplasia (LIN) patients
|
|
|
|---|---|
|
| |
| Male | 77 (94) |
| Female | 5 (6) |
|
| |
| Glottis–hypoglottis | 43 (53) |
| Supraglottis | 39 (47) |
|
| |
| Mild | 21 (47) |
| Moderate | 8 (19) |
| Severe | 53 (64) |
|
| |
| No | 35 (43) |
| LIN | 10 (12) |
| SCC | 37 (45) |
SCC=squamous cell carcinoma.
Figure 1(A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (B) ( × 150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( × 150). (E and F) A representative case of moderate dysplasia showing a strong immunostaining for OPN (E) and a CD44v6 positivity involving the lower two-thirds of the epithelium (F) ( × 250). (G and H) A case of high-grade dysplasia showing strong immunostaining for OPN (G) and CD44v6 positivity up to the upper third of the epithelium (H) ( × 400).
OPN and CD44v6 positivity in laryngeal intraepithelial neoplasia at different degree
|
|
|
|
|---|---|---|
| Mild (21) | 16/21 (+) | 16/21 (L) |
| 1/21 (++) | 2/21 (M) | |
| 4/21 (+++) | 3/21 (F) | |
| Moderate (8) | 3/8 (+) | 2/8 (L) |
| 1/8 (++) | 3/8 (M) | |
| 4/8 (+++) | 3/8 (F) | |
| Severe (53) | 16/53 (+) | 15/53 (L) |
| 11/53 (++) | 12/53 (M) | |
| 26/53 (+++) | 26/53 (F) |
OPN=osteopontin.
Osteopontin and CD44v6 expression were assessed by immunohistochemistry and scored respectively as follows: +=<10% positive cells; ++=10–50% positive cells; and +++=50–100% positive cells; L=lower; M=lower and middle; and F=full-thickness involvement of the epithelial layers.
Correlation of osteopontin and CD44v6 expression in all laryngeal intraepithelial neoplasia (LIN) patients combined or grouped by degree of dysplasia
|
|
|
|
|---|---|---|
| Combined (82) | 0.8231 | <0.0001 |
| Mild (21) | 0.9941 | <0.0001 |
| Moderate (8) | 0.2622 | =0.5304 |
| Severe (53) | 0.7957 | <0.0001 |
Note: Correlation between osteopontin and CD44v6 expression in LIN patients analysed by Spearman's rank correlation test.
Correlation coefficient (rs) and Ps are shown (Ps<0.05 was considered significant).
Figure 2(A and C) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the lower third of the epithelium (C) ( × 150). (B and D) The same samples as in (A) negative for OPN immunostaining after incubation with isotype control antiserum (B) ( × 150), and the same sample as in (C) negative for CD44v6 immunostaining after incubation with isotype control antiserum (D) ( × 150).
Figure 3(A and B) An area of incomplete squamous metaplasia, negative for OPN (A), and CD44v6 (B) immunostaining ( × 250). (C and D) Another case of incomplete squamous metaplasia (patient with a history of laryngeal SCC), showing an intense OPN (C) and CD44v6 (D) immunostaining ( × 106).
Figure 4Osteopontin and CD44v6 staining in laryngeal dysplasia negatively correlates with disease-free survival. Kaplan–Meier survival plots for patients grouped on the basis of the OPN (A) or CD44v6 (B) expression level. (A) Patients were stratified into three categories (+ (n=21), ++ (n=5), and +++ (n=25)) based on OPN immunostaining intensity. (B) Patients were stratified into three categories (L (n=18), M (n=10), and F (n=23) based on the thickness of CD44v6 staining). The P-value was determined by a two-sided log-rank test.
Correlation of osteopontin and CD44v6 expression in all laryngeal intraepithelial neoplasia (LIN) patients combined or grouped by relapse
|
|
|
|
|---|---|---|
| Combined (82) | 0.8231 | <0.0001 |
| no (35) | 0.8133 | <0.0001 |
| LIN (10) | 0.5976 | =0.0734 |
| SCC (37) | −0.7892 | <0.0001 |
SCC=squamous cell carcinoma.
Note: Absence of relapse (no), recurrence of dysplasia (LIN), progression to carcinoma (SCC).
Correlation between osteopontin and CD44v6 expression in LIN patients analysed by Spearman's rank correlation test. Correlation coefficient (rs) and Ps are shown (Ps<0.05 was considered significant).
Pearson's test
|
|
| |
|---|---|---|
|
| ||
| OPN | 13.425 | 0.0094 |
| CD44v6 | 16.198 | 0.0028 |
|
| ||
| OPN | 21.780 | <0.0002 |
| CD44v6 | 9.567 | 0.0484 |
|
| ||
| Combined (82) | 73.026 | <0.0001 |
| No (35) | 32.694 | <0.0001 |
| LIN (10) | 10.000 | 0.0067 |
| SCC (37) | 34.857 | <0.0001 |
LIN=laryngeal intraepithelial neoplasia; SCC=squamous cell carcinoma.
Note: Absence of relapse (no), recurrence of dysplasia (LIN), and progression to carcinoma (SCC).